Oncotarget

Meta-Analysis:

Altered long non-coding RNAs predict worse outcome in osteosarcoma patients: evidence from a meta-analysis

Yanliang Yang _, Shunli Wang and Teng Li

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35234-35243. https://doi.org/10.18632/oncotarget.16470

Metrics: PDF 1143 views  |   HTML 1434 views  |   ?  


Abstract

Yanliang Yang1, Shunli Wang1 and Teng Li1

1 Bone Tumour & Bone Disease Department I, Zhengzhou Orthopaedics Hospital, Zhengzhou Orthopedics Hospital Affiliated to Henan University, Henan, China

Correspondence to:

Yanliang Yang, email:

Keywords: osteosarcoma, lncRNA, prognosis, meta-analysis

Received: November 01, 2016 Accepted: March 10, 2017 Published: March 22, 2017

Abstract

Long non-coding RNAs (lncRNAs) are emerging as promising prognostic biomarkers in an expanding list of malignant neoplasms. Here, we sought to investigate the strength of associations between lncRNA signatures and clinical outcomes in osteosarcoma. We conducted a systematic search of the online databases from inception to July 2016. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for the primary endpoints of overall survival (OS), progression-free survival (PFS) or event-free survival (EFS) were extracted and meta-analyzed. Our results manifested that altered lncRNAs expression was markedly associated with worse OS (univariate analysis: HR = 3.20, 95% CI: 2.42-4.24, P = 0.000; multivariate analysis: HR = 2.66, 95% CI: 1.92-3.69, P = 0.000), PFS (HR = 2.05, 95% CI: 1.32-3.18, P = 0.001) and EFS (HR = 4.37, 95% CI: 1.64-11.66, P = 0.003) times among osteosarcoma patients. In the pooled analyses stratified by clinicopathological features, levels of lncRNAs were closely correlated with tumor size (pooled P = 0.001), tumor stage (pooled P = 0.003), and distant metastasis (pooled P = 0.002) in osteosarcoma. The results obtained in our work suggest that altered lncRNA signatures predict unfavorable clinical outcomes and are acceptable to be potential prognostic biomarkers in forecasting prognosis of osteosarcoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16470